CP 293121
Latest Information Update: 21 Mar 2000
Price :
$50 *
At a glance
- Originator Pfizer
- Class Anti-inflammatories; Antiasthmatics
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 21 Mar 2000 Profile reviewed but no significant changes made
- 22 May 1998 New profile
- 22 May 1998 Discontinued-Preclinical for Asthma in USA (Unknown route)